Losartan/hydrochlorothiazide

Losartan/hydrochlorothiazide
Combination of
Losartan	Angiotensin II receptor antagonist
Hydrochlorothiazide	Thiazide diuretic
Clinical data
Trade names	Anzaplus, Cozaar comp, Hyzaar, Ocsaar Plus
Pregnancy category	US: D (Evidence of risk)
Routes of administration	Oral
Legal status	℞ (Prescription only)
Identifiers
ATC code	C09DA01 (WHO)
PubChem	CID 24783652
KEGG	D07895

Losartan/hydrochlorothiazide is a combination drug used as an antihypertensive, consisting of losartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a diuretic).

The losartan/hydrochlorothiazide combination preparation is marketed by Merck under the trade name Hyzaar and by Xeno Pharmaceuticals under the name Anzaplus. Merck, Sharp & Dohme market it as Ocsaar Plus in Israel. It is marketed as Cozaar comp in Sweden and South Africa.

In 2010, the patent for the combination expired, and a number of pharmaceutical companies promptly filed and received approval to sell the generic losartan, with and without hydrochlorothiazide, in the United States.^[1]

Dosage

The recommended dosage of losartan-hydrochlorothiazide for adults with high blood pressure (hypertension) will vary between losartan-hydrochlorothiazide 50 mg/12.5 mg and losartan-hydrochlorothiazide 100 mg/25 mg once a day. Based on the initial blood pressure response and/or losartan-hydrochlorothiazide side effects, the dosage may be increased or decreased. With each change in dosage, it may take up to a month to see the full effect of losartan-hydrochlorothiazide on lowering blood pressure.

References

↑ http://web.archive.org/web/20100429175034/http://www.marketwatch.com:80/story/teva-announces-final-approval-of-generic-hyzaarr-and-cozaarr-2010-04-07. Archived from the original on April 29, 2010. Retrieved April 20, 2011. Missing or empty |title= (help)

Antihypertensives: agents acting on the renin–angiotensin system (C09)

ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril Dicarboxylate-containing: Enalapril^# Benazepril Cilazapril Delapril Imidapril Lisinopril (+HCT) Moexipril Perindopril Quinapril (+HCT) Ramipril Spirapril Temocapril Trandolapril Phosphonate-containing: Fosinopril (+HCT) Other/ungrouped: Alacepril

AIIRAs/ ("-sartan")	Azilsartan Candesartan Eprosartan Fimasartan Irbesartan Losartan (+HCT) Olmesartan (+amlodipine) Tasosartan^§ Telmisartan (+HCT) Valsartan (+HCT, +amlodipine, +sacubitril)

Renin inhibitors/ ("-kiren")	Aliskiren (+amlodipine, +amlodipine and HCT) Remikiren^§

^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

This article is issued from Wikipedia - version of the Thursday, March 10, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.